| 1 |
35395766 | The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide. | 2022 Apr 8 |
1 |
| 2 |
35397772 | Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study. | 2022 Jun |
3 |
| 3 |
35475157 | Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB study. | 2022 Jan |
1 |
| 4 |
32529950 | Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. | 2021 Apr |
1 |
| 5 |
32739115 | The Impact of Treatment Crossover and Prostate-specific Antigen Flare with Enzalutamide and Abiraterone in Metastatic Castrate Resistant Prostate Cancer. | 2021 Jan |
1 |
| 6 |
33426491 | Usefulness of robot-assisted radical prostatectomy in a patient with oligometastatic castration-resistant prostate cancer. | 2021 Jan |
1 |
| 7 |
33571020 | Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer. | 2021 Apr |
2 |
| 8 |
33617303 | TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. | 2021 Apr 20 |
2 |
| 9 |
33856892 | Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries. | 2021 Apr |
1 |
| 10 |
33958536 | Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment? | 2021 Sep 1 |
1 |
| 11 |
34221973 | Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience. | 2021 |
1 |
| 12 |
34313171 | The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis. | 2021 Jan-Dec |
1 |
| 13 |
34597353 | Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer. | 2021 |
1 |
| 14 |
34621011 | Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. | 2021 Oct 7 |
1 |
| 15 |
34784577 | Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. | 2021 Dec |
2 |
| 16 |
34804841 | ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis. | 2021 Oct |
1 |
| 17 |
31307958 | Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. | 2020 Apr |
1 |
| 18 |
31564004 | Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study. | 2020 Mar |
2 |
| 19 |
31830211 | Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. | 2020 Feb 1 |
1 |
| 20 |
31972048 | Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. | 2020 Apr |
1 |
| 21 |
31972568 | Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis. | 2020 Apr |
1 |
| 22 |
32160733 | [A Case of Primary Central Nervous System Lymphoma that Developed during the Treatment of Castration-Resistant Prostate Cancer]. | 2020 Feb |
1 |
| 23 |
32274540 | [Treatment of metastatic, castration-resistant prostate cancer]. | 2020 Jun |
2 |
| 24 |
32414694 | Low-Dose Enzalutamide in Late-Elderly Patients (≥ 75 Years Old) Presenting With Metastatic Castration-Resistant Prostate Cancer. | 2020 Dec |
1 |
| 25 |
32469184 | Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. | 2020 Jun 4 |
3 |
| 26 |
32929792 | Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide. | 2020 Dec |
1 |
| 27 |
33010985 | Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. | 2020 Dec |
7 |
| 28 |
33217255 | Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. | 2020 |
2 |
| 29 |
33435657 | [A Case of Castration-Resistant Prostate Cancer after Prostatectomy Treated with Resection of A Solitary Metastatic Site]. | 2020 Dec |
1 |
| 30 |
30119985 | Managing Nonmetastatic Castration-resistant Prostate Cancer. | 2019 Feb |
2 |
| 31 |
30520109 | Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response. | 2019 Mar |
1 |
| 32 |
30611646 | Cell-based evidence regarding the role of FSH in prostate cancer. | 2019 Apr |
1 |
| 33 |
30741370 | Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study. | 2019 Jul |
2 |
| 34 |
30971225 | Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study). | 2019 Apr 11 |
1 |
| 35 |
31262916 | Flutamide as an Alternative Anti-androgen Agent and Predictor of the Efficacy of Novel Androgen Receptor-targeted Agents. | 2019 Jul |
1 |
| 36 |
31274110 | Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. | 2019 Nov |
10 |
| 37 |
31329516 | ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. | 2019 Nov 10 |
1 |
| 38 |
31430900 | Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort. | 2019 Aug 19 |
1 |
| 39 |
31527212 | Leptomeningeal involvement by prostate carcinoma an ominous head of a well-known Hydra. | 2019 Sep 16 |
1 |
| 40 |
31689828 | Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: A systematic review and meta-analysis of randomized controlled trials. | 2019 Nov |
1 |
| 41 |
32743396 | Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a significant decrease in the prostate-specific antigen level and improvement in radiographic findings. | 2019 May |
2 |
| 42 |
28827103 | Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. | 2018 Jan |
1 |
| 43 |
28867562 | Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results. | 2018 Feb |
1 |
| 44 |
29248236 | Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. | 2018 Jan |
2 |
| 45 |
29521011 | Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men. | 2018 May |
4 |
| 46 |
29843816 | Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide. | 2018 May 29 |
1 |
| 47 |
29949494 | Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. | 2018 Jun 28 |
3 |
| 48 |
30028657 | Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. | 2018 Sep 1 |
2 |
| 49 |
30054264 | Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial. | 2018 Jul 27 |
1 |
| 50 |
30126765 | Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong. | 2018 Oct |
1 |